

1 **Sleep duration irregularity and risk for incident cardiovascular disease in the UK Biobank**

2 Tianyi Huang,<sup>1</sup> Sina Kianersi,<sup>2</sup> Heming Wang,<sup>2,3</sup> Kaitlin S. Potts,<sup>2</sup> Raymond Noordam,<sup>4</sup> Tamar  
3 Sofer,<sup>2,5,6</sup> Martin K. Rutter,<sup>7,8</sup> Susan Redline<sup>2,9</sup>

4

5 <sup>1</sup>Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National  
6 Institute on Aging, Baltimore, MD, USA

7 <sup>2</sup>Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's  
8 Hospital, Boston, MA, USA

9 <sup>3</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA

10 <sup>4</sup>Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University  
11 Medical Center, Leiden, The Netherlands

12 <sup>5</sup>Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA

13 <sup>6</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA

14 <sup>7</sup>Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences,  
15 University of Manchester, Manchester, UK

16 <sup>8</sup>Diabetes, Endocrinology and Metabolism Centre, Manchester Royal Infirmary, Manchester  
17 University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester  
18 Academic Health Science Centre, Manchester, UK

19 <sup>9</sup>Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA

20

21 Corresponding author:

22 Tianyi Huang, MSc, ScD  
23 251 Bayview Blvd., NIH Biomedical Research Center, Ste.100, Room 09C216, Baltimore, MD  
24 21224  
25 Phone: (410) 558-8388  
26 Email: [tianyi.huang@nih.gov](mailto:tianyi.huang@nih.gov)

27

28

29

30

31

32

33 **Abstract**

34 **Background:** Emerging evidence supports a link between circadian disruption as measured by  
35 higher night-to-night variation in sleep duration and increased risk of cardiovascular disease  
36 (CVD). It remains unclear whether this association varies by CVD types or may be modified by  
37 average sleep duration and genetic risk for CVD.

38 **Methods:** Our prospective analysis included 86,219 UK Biobank participants who were free  
39 from CVD when completing 7 days of accelerometer measurement in 2013-2016. Sleep  
40 irregularity was evaluated by the standard deviation (SD) of accelerometer-measured sleep  
41 duration over 7 days. Incident major CVD events, defined as fatal or nonfatal myocardial  
42 infarction (MI) and stroke, were identified through linkage to Hospital Episode Statistics data  
43 until May 31, 2022. Multivariable-adjusted Cox proportional hazard models were used to  
44 estimate hazard ratios (HRs) and 95% CIs for associations of sleep duration SD with risk for  
45 major CVD events overall and for MI and stroke separately.

46 **Results:** We documented 2,310 incident cases of major CVD events (MI: 1,183, stroke: 1,175)  
47 over 636,258 person-years of follow-up. After adjusting for sociodemographic factors and family  
48 history of CVD, the HR (95% CI) associated with a 1-hour increase in sleep duration SD was  
49 1.19 (1.10, 1.27) for CVD ( $p$ -trend<0.0001), 1.23 (1.11, 1.35) for MI ( $p$ -trend<0.0001), and 1.17  
50 (1.05, 1.29) for stroke ( $p$ -trend=0.003). Additional adjustment for lifestyle factors, co-morbidities  
51 and sleep-related factors modestly attenuated these associations. Higher sleep irregularity was  
52 associated with higher CVD risk irrespective of genetic risk ( $p$ -interaction=0.43), but this  
53 association was stronger among individuals with longer average sleep duration >8 hours ( $p$ -  
54 interaction=0.006)

55 **Conclusions:** Higher night-to-night variation in accelerometer-measured sleep duration was  
56 associated with consistently higher risks for major CVD events. The association did not seem to  
57 be modified by genetic risk for CVD and was more pronounced in long sleepers.

58 **Acknowledgements:** This research was supported by NIH grant R01HL155395, UK Biobank  
59 project 85501 and the Intramural Research Program of the NIH, National Institute on Aging. SK  
60 was supported by the American Heart Association Postdoctoral Fellowship (24POST1188091).

61 Introduction

62 Sleep health is increasingly recognized as a crucial component of a healthy lifestyle  
63 especially for promoting cardiovascular well-being. Numerous prospective epidemiologic studies  
64 have linked self-reported short and long sleep duration with higher cardiovascular disease  
65 (CVD) incidence and mortality.<sup>1</sup> Recent results based on objective sleep assessment or  
66 Mendelian randomization also support increased CVD risk and mortality associated with short  
67 sleep, although the evidence for long sleep duration is weaker and less consistent.<sup>2-4</sup> Built upon  
68 the mounting evidence, the American Heart Association in 2022 updated the construct of  
69 cardiovascular health from Life's Simple 7 to Life's Essential 8, highlighting the role of sleep  
70 health in CVD prevention and focusing on advocating 7-8 hours of habitual sleep.<sup>5</sup>

71 Notably, the mean level of sleep duration, either estimated by self-reports or averaged  
72 across multiple nights of objective monitoring, only captures one aspect of sleep health.<sup>6,7</sup>  
73 Maintaining consistent sleep-wake cycles is essential for achieving restful, restorative sleep and  
74 synchronizing internal circadian rhythms with the social and natural environment. Growing  
75 evidence suggests that night-to-night variability in sleep duration, independent of mean sleep  
76 duration, is a novel risk factor for cardiometabolic disease and mortality.<sup>8-12</sup> In the Multi-Ethnic  
77 Study of Atherosclerosis (MESA), we reported that higher sleep duration irregularity measured  
78 by 7-day standard deviation (SD) in actigraphy-based sleep duration was significantly  
79 associated with greater subclinical atherosclerotic burden and higher CVD risk after accounting  
80 for traditional CVD risk factors and average sleep duration.<sup>8,9</sup> However, the modest sample size  
81 in MESA constrained our ability to fully explore potential heterogeneity in the association  
82 between sleep duration irregularity and CVD risk by major CVD types. It also remains unclear  
83 whether sleep duration irregularity, a behavior amenable to modification, may interact with  
84 genetic susceptibility to CVD or average sleep duration to influence CVD risk.

85 Leveraging the large-scale accelerometer-measured sleep data from the UK Biobank,  
86 we evaluated the prospective associations of 7-day variability in sleep duration with incidence of

87 major adverse cardiovascular events overall and separately for myocardial infarction (MI) and  
88 stroke. We hypothesized that higher variability in sleep duration would exacerbate CVD risk  
89 similarly for MI and stroke, with stronger associations in individuals with a greater genetic  
90 predisposition to CVD or shorter average sleep duration.

## 91 Methods

92 *Study population.* The UK Biobank is a large prospective cohort study initiated in 2006-  
93 2010, when over 500,000 participants aged 40-69 years completed baseline physical,  
94 sociodemographic, and medical assessments in one of 22 centers in the UK.<sup>13</sup> Participants  
95 were prospectively followed for occurrence of a wide range of health outcomes, with collection  
96 of additional exposure and phenotypic information through further assessment. In 2013-2015, a  
97 subsample of 103,712 participants completed an accelerometer study over a 7-day period.<sup>14</sup>  
98 Our analysis included 92,884 participants who provided  $\geq 5$  days of accelerometer sleep data. Of  
99 these, we further excluded participants with indicators for poor data quality (e.g., insufficient  
100 wear time;  $n=3,355$ ), extreme sleep values (e.g., average sleep duration  $< 3$  hours or  $> 12$  hours  
101 or sleep duration SD  $> 4$  hours;  $n=114$ ), pre-existing CVD prior to the end of accelerometer  
102 assessment ( $n=3,193$ ), or loss to follow-up ( $n=3$ ), leaving 86,219 for analysis. The UK Biobank  
103 received approval by the NHS North-West Multi-Centre Research Ethics Committee. All  
104 participants provided written informed consent. The present study was completed under the UK  
105 Biobank project 85501.

106 *Sleep assessment.* Between 2013-2015, participants who provided a valid email address  
107 were invited to wear a wrist accelerometer (Axivity AX3) for 7 days.<sup>14</sup> A total of 103,712  
108 participants returned the data, which were further processed by the R package GGIR consistent  
109 with prior research.<sup>15,16</sup> Sleep periods and episodes were identified based on 5-second epoch  
110 time-series accelerometer signals, and determined as the longest block of combined inactivity  
111 bouts lasting  $\geq 30$  min. This algorithm has been validated against polysomnography to  
112 accurately detect sleep periods in the absence of sleep diary records.<sup>17</sup> For each participant, we

113 calculated the mean and SD of sleep duration across all available days, and the sleep duration  
114 SD was used as the measure for sleep duration irregularity. Sleep efficiency was defined as  
115 proportion of sleep duration within the sleep period window (i.e., the time between the start and  
116 end of the longest inactivity block).

117 At UK Biobank enrollment (2.8 to 9.7 years prior to the accelerometer study),  
118 participants also self-reported several habitual sleep symptoms or patterns, with each assessed  
119 using a single, representative question carefully chosen from commonly used instruments.  
120 These sleep metrics included sleep duration, insomnia symptoms, chronotype, snoring and  
121 daytime sleepiness.<sup>18</sup> Sleep apnea was identified through a combination of self-reported  
122 diagnosis and medical records.<sup>19</sup>

123 *Ascertainment of CVD events.* Incidence of major CVD events was defined as the first  
124 occurrence of MI or stroke that resulted in hospitalization or death. Hospital admissions were  
125 identified through linkage to the Hospital Episode Statistics, and date of death was identified  
126 based on death certificates from the National Death Register. Classification of fatal and nonfatal  
127 CVD events was recorded using the International Classification of Diseases, Tenth Revision  
128 (ICD-10). We considered ICD-10 codes I21-23 for MI and I60-64 for stroke.

129 *Statistical analysis.* For each participant, we calculated person-time of follow-up from the  
130 end date of the accelerometer study until the earliest date of major CVD events, death, or end of  
131 follow-up (May 31, 2022). Cox proportional hazards regression was used to estimate the  
132 association between sleep duration SD and risk of developing CVD events over follow-up. We  
133 did not detect significant deviation from the proportional hazards assumption by testing the time-  
134 by-exposure interaction ( $p$  for interaction=0.36). Sleep duration SD was modeled as a  
135 continuous variable (per 1-hour) as well as in categories ( $\leq 30$  [ref], 31-45, 46-60, 61-90,  $>90$   
136 min). The primary model adjusted for age, sex, self-reported race and ethnicity, Townsend  
137 deprivation index, work schedules, and family history of CVD. Lifestyle, co-morbidities and sleep  
138 disturbances may be consequences of irregular sleep duration, therefore acting in the pathway

139 linking sleep duration SD and CVD risk. To avoid potential overadjustment,<sup>20</sup> we considered  
140 these covariates in separate multivariable models. In the second model, we further controlled for  
141 BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of  
142 hypertension, dyslipidemia, diabetes and depression. We additionally added to the third model  
143 objectively-measured average sleep duration and sleep efficiency, self-reported insomnia  
144 symptoms, chronotype and sleepiness, and clinically diagnosed sleep apnea. All analyses were  
145 performed for major CVD events overall and for MI and stroke separately.

146 To test the robustness of the results, we performed several sensitivity analyses. First,  
147 given that the COVID-19 pandemic may have disrupted healthcare, impacting cardiovascular  
148 testing and diagnosis and resulting in outcome misclassification and potentially biased  
149 associations,<sup>21</sup> we repeated the analysis with the end of follow-up as March 23, 2020, the start  
150 of the UK national lockdown. Second, we excluded CVD events occurring within the first year  
151 after the accelerometer study to assess the impact of preclinical CVD and symptoms on sleep  
152 duration irregularity (i.e., reverse causation). Third, considering that variation in sleep schedules  
153 between weekdays versus weekend (e.g., weekend catch-up sleep) is an important contributor  
154 to day-to-day variability in sleep duration across the week<sup>22</sup>, we assessed whether the  
155 observed associations for sleep duration irregularity persisted beyond weekday-weekend  
156 variation by focusing on sleep duration SD across weekdays only. Fourth, we examined the  
157 associations separately for ischemic and hemorrhagic strokes, as these stroke subtypes may  
158 have distinct etiologic origins.<sup>23</sup>

159 We conducted subgroup analysis by age, sex, race, average sleep duration, polygenic  
160 risk score (PRS) for CVD, and family history of CVD based on the primary multivariable model.  
161 Subgroup heterogeneity was evaluated by the likelihood ratio test of the multiplicative  
162 interaction with the continuous sleep duration SD. Of *a priori* interest, we examined the joint  
163 associations between sleep duration SD ( $\leq 30$ , 31-45, 46-60, 61-90,  $>90$  min) and PRS (low,  
164 medium, high) or average sleep duration ( $<7$ , 7-8,  $>8$  hrs) with CVD outcomes. Participants with

165 sleep duration SD <30 min and low PRS or 7-8 hrs of average sleep duration were used as the  
166 reference group in the joint analyses. All statistical analyses were performed using SAS version  
167 9.4 (SAS Institute).

## 168 Results

169 Of 86,219 participants, the mean (SD) for 7-day SD in sleep duration was 56 (33)  
170 minutes, with 25,434 (29.5%) having sleep duration SD>60 minutes. Participants with higher  
171 sleep duration irregularity, assessed by sleep duration SD, tended to be younger, female, non-  
172 white, socioeconomically disadvantaged and employed, especially in occupations requiring shift  
173 work, and were more likely to have higher BMI and currently smoke (**Table 1**). Family history of  
174 CVD was slightly less common in participants with higher sleep duration SD, but no clear  
175 difference was observed when genetic risk for CVD was assessed by PRS. Although the  
176 prevalence of metabolic disorders (dyslipidemia, hypertension, diabetes) did not differ  
177 appreciably across categories of sleep duration SD, the prevalence of depression was higher  
178 among participants with greater sleep duration SD. With increasing sleep duration SD, there  
179 was a notable trend towards shorter objective sleep duration, particularly among those with  
180 sleep duration SD $\geq$ 90 minutes. Additionally, irregular sleepers exhibited lower sleep efficiency  
181 and were more likely to self-report as evening chronotypes.

## 182 **Associations of sleep duration irregularity and cardiovascular disease risk**

183 Over 636,258 person-years of follow-up (median: 7.5 years), 2,310 participants  
184 developed a major CVD event (1,183 MI and 1,175 stroke). After adjusting for  
185 sociodemographic factors and family history of CVD, the HR (95% CI) for major CVD events  
186 was 1.10 (0.97, 1.26) for those with a sleep duration SD of 31-45 minutes, 1.19 (1.04, 1.37) for  
187 46-60 minutes, 1.33 (1.15, 1.53) for 61-90 minutes, and 1.40 (1.18, 1.65) for >90 minutes,  
188 compared with participants with a sleep duration SD  $\leq$ 30 minutes (p for trend<0.0001; **Table 2**).  
189 Similar positive associations were observed for MI and stroke separately. The HR (95% CI)  
190 associated with a 1-hour increase in sleep duration SD was 1.19 (1.10, 1.27) for CVD, 1.23

191 (1.11, 1.35) for MI, and 1.17 (1.05, 1.29) for stroke. Further adjustment for lifestyle factors, co-  
192 morbidities and sleep-related factors only modestly attenuated the associations. For example,  
193 the HR (95% CI) for major CVD events per 1-hour increment in sleep duration SD was 1.15  
194 (1.07, 1.24) after further adjusting for lifestyle factors and co-morbidities (p for trend=0.0001)  
195 and 1.13 (1.05, 1.22) after additionally controlling for sleep-related factors (p for trend=0.001).

## 196 **Sensitivity analyses**

197 We observed somewhat stronger associations when the analysis was censored at the  
198 start of the UK COVID-19 lockdown (**Supplemental Table 1**). For example, the HR (95% CI) for  
199 CVD after adjustment for sociodemographic factors and family history of CVD was 1.15 (0.98,  
200 1.36) for sleep duration SD of 31-45 minutes, 1.28 (1.08, 1.51) for 46-60 minutes, 1.42 (1.19,  
201 1.69) for 61-90 minutes, and 1.51 (1.23, 1.85) for >90 minutes, compared with sleep duration  
202 SD ≤30 minutes (p for trend<0.0001). Slightly weaker but significant positive associations were  
203 observed in sensitivity analyses excluding CVD events diagnosed within the first year after the  
204 sleep assessment (**Supplemental Table 2**) or only evaluating sleep duration variability across  
205 weekdays (**Supplemental Table 3**). When examining stroke risk by type, the higher stroke risk  
206 associated with irregular sleep duration was primarily attributed to ischemic stroke rather than  
207 hemorrhagic stroke (**Supplemental Table 4**).

## 208 **Subgroup associations**

209 The higher CVD risk associated with irregular sleep duration was more pronounced  
210 among participants ≥60 years versus <60 years (p-interaction=0.04) and among participants  
211 with longer average sleep duration >8 hours (p-interaction=0.006; **Table 3**). We observed a  
212 stronger positive association between sleep duration irregularity and CVD risk among  
213 participants with a family history of CVD compared to those without the history (p-  
214 interaction=0.03). However, such potential gene-sleep interactions were not observed when  
215 genetic predisposition was assessed by PRS (p-interaction=0.43), and irregular sleep duration  
216 was associated with higher CVD risk regardless of the PRS for CVD. There was no significant



217 difference in the association by sex (p-interaction=0.09) or race (p-interaction=0.42), although  
218 the race-stratified analysis was underpowered. These subgroup differences remained largely  
219 the same when MI and stroke were examined individually, except that the association for stroke  
220 did not differ by family history of CVD and was significantly stronger in men than in women  
221 **(Supplemental Table 5).**

## 222 **Joint associations**

223 Irregular sleep duration was consistently associated with increases in CVD risk across  
224 tertiles of PRS for CVD (**Figure 1a**). Compared with individuals with low genetic risk and a sleep  
225 duration SD≤30 min, the highest CVD risks were observed in individuals with high genetic risk  
226 and a sleep duration SD 61-90 minutes (HR: 2.52; 95% CI: 1.94, 3.28) or >90 minutes (HR:  
227 2.39; 95% CI: 1.78, 3.22). Further, higher risks for MI or stroke associated with irregular sleep  
228 duration were observed across various genetic risk categories for MI or stroke, except for  
229 individuals with low genetic risk for stroke, where no clear association was found  
230 **(Supplemental Figure 1)**. Compared with individuals with a sleep duration SD ≤30 min and an  
231 optimal sleep duration of 7-8 hours, the elevated CVD risk associated with a large sleep  
232 duration SD >90 minutes was more pronounced in long sleepers >8 hrs (HR: 1.95; 95% CI:  
233 1.29, 2.93) than in short sleepers <7 hrs (HR: 1.42; 95% CI: 1.15, 1.77; **Figure 1b**). The joint  
234 association patterns were similar for MI and stroke individually (**Supplemental Figure 2**).

## 235 Discussion

236 This prospective study in the UK Biobank shows higher CVD risks among individuals  
237 with irregular sleep duration after accounting for established CVD risk factors. The observed  
238 increase in CVD risk associated with irregular sleep duration was similar for MI and stroke.  
239 Although irregular sleep duration was consistently associated with higher CVD risk irrespective  
240 of the genetic risk profile or the average sleep duration, the association was more pronounced  
241 among individuals with sleep duration longer than 8 hours.

242 Consistent with prior studies linking sleep irregularity with higher risks for CVD<sup>8</sup> and total  
243 mortality<sup>10-12</sup> as well as with CVD risk factors including atherosclerotic development,<sup>9</sup> metabolic  
244 syndrome<sup>24</sup> and diabetes,<sup>25</sup> our findings provide further evidence supporting the congruent  
245 associations of irregular sleep duration with risk of MI and stroke, particularly ischemic stroke.  
246 This suggests that irregular sleep duration may modulate common pathways leading to  
247 ischemic cardiovascular events. These pathways include dysregulation of blood pressure,  
248 glucose/lipid metabolism, inflammation, endothelial function, and thrombotic events induced by  
249 circadian disruption,<sup>26-31</sup> as well as adverse effects of intermittent sleep curtailment on  
250 sympathetic and hormonal activities.<sup>32-34</sup> Given that irregular sleep duration can occur on a daily,  
251 habitual basis, the resulting biologic changes may act as triggers for adverse cardiovascular  
252 events, significantly increasing the chance of developing CVD events over the long term. More  
253 direct evidence is needed to fully understand the mechanisms underlying the association  
254 between irregular sleep duration and CVD risk.

255 Of note, the association observed in the current study was more modest compared to  
256 our prior investigation in MESA.<sup>8</sup> Specifically, the HR (95% CI) for CVD was 1.19 (1.10, 1.27) in  
257 the UK Biobank and 1.41 (1.12, 1.79) in MESA. While the smaller sample size in MESA may  
258 contribute to less accurate estimates, key differences between the cohorts could also explain  
259 this. For example, MESA included older individuals (mean age: 69 vs 62 years), and our  
260 subgroup analysis suggests that older individuals may be more vulnerable to the negative  
261 cardiovascular effects of irregular sleep duration. The prevalence of irregular sleep duration also  
262 differed, with 39.5% in MESA having a 7-day sleep duration SD >90 min compared to 10.4% in  
263 the UK Biobank. Further, the UK Biobank analysis included the COVID-19 period, which,  
264 according to sensitivity analysis, led to a weaker overall association. Greater misclassification of  
265 CVD outcomes due to delayed or missed diagnostic testing during the COVID-19 period,<sup>21</sup> as  
266 well as inaccuracy of using data from 2013-2015 to reflect pandemic sleep duration irregularity  
267 when many were staying at home, may have both attenuated the observed association.

268 Consistent with our initial hypothesis, irregular sleep duration was more strongly  
269 associated with CVD risk among individuals with a family history of CVD, an indirect measure  
270 for inherited susceptibility. However, such a gene-sleep interaction was not present when PRS  
271 was used as the direct, quantitative measure for genetic susceptibility. A positive association  
272 between irregular sleep duration and CVD risk was consistently observed in individuals with low,  
273 medium, or high genetic risk, similar to a previous UK Biobank study evaluating gene-sleep  
274 interactions for CVD risk based on self-reported sleep traits.<sup>18</sup> The inconsistent findings may be  
275 attributed to the fact that PRS and family history represent independent and complementary  
276 rather than interchangeable measures for inherited disease susceptibility.<sup>35</sup> Family history  
277 encompasses additional lifestyle and environmental factors shared within families that may  
278 influence the associations beyond genetic susceptibility. It is also possible that irregular sleep  
279 duration may interact with specific genetic pathways to influence CVD risk. Significant gene-  
280 sleep interactions may be more likely to be observed with pathway-specific PRS rather than the  
281 overall CVD PRS,<sup>19</sup> which requires future investigation.

282 Intriguingly, although shorter sleepers (<7 hours) tended to exhibit greater sleep duration  
283 irregularity, longer sleepers (>8 hours) seemed more susceptible to the adverse effects of sleep  
284 duration irregularity on CVD risk. This suggests that excessive catch-up sleep, which resulted in  
285 both longer average sleep duration and larger variability, may not compensate for sleep debt but  
286 conversely may lead to circadian dysregulation and increased CVD risk.<sup>36</sup> Previous research on  
287 weekday-weekend differences in sleep duration only found beneficial relationships of shorter,  
288 but not longer, weekend catch-up sleep with inflammation and mortality.<sup>37,38</sup> Our joint analysis  
289 suggests that irregular sleep duration coupled with long sleep duration conferred the highest  
290 CVD risk. Other studies reported that sleep irregularity was a stronger predictor of mortality than  
291 either sleep duration<sup>11</sup> or sleep apnea.<sup>12</sup> As a result, a recent consensus statement from the  
292 National Sleep Foundation highlighted the importance of sleep regularity for health and

293 performance,<sup>39</sup> calling for increased research and public initiatives to optimize sleep regularity at  
294 the population level.

295         The strengths of the study included the prospective design, large-scale accelerometer  
296 measurements, systematic identification of incident CVD outcomes through ICD-coded health  
297 records, and the availability of important covariates including genetic risk. However, the  
298 analytical sample from the UK Biobank included primarily white British participants with  
299 relatively high socioeconomic background, potentially limiting the generalizability of our findings  
300 to other populations. Nonetheless, the consistency with results from the racial and ethnic  
301 diverse MESA cohort<sup>8</sup> suggests that the impact of irregular sleep duration on CVD risk may  
302 have broader implications. We relied on accelerometer measurement taken over 7 days to  
303 quantify irregular sleep duration, which may not reliably represent long-term habitual sleep  
304 patterns that are relevant for CVD pathogenesis, particularly during the pandemic. This  
305 limitation could weaken the observed associations and may partially explain why stronger  
306 associations were observed when the COVID-19 period was excluded from the analysis.  
307 Despite the possibility for residual confounding given that many covariates were assessed at the  
308 UK Biobank baseline 2.8 to 9.7 years prior to the accelerometer study, it is unlikely that  
309 misclassification of time-varying covariates (e.g., work schedules) could fully account for the  
310 associations observed. Finally, our study was observational by nature, and further evidence is  
311 needed to establish the causal relationship between irregular sleep duration and CVD risk.

312         In summary, irregular sleep duration as characterized by high day-to-day variation in  
313 habitual sleep duration over a 7-day period was associated with higher CVD risk overall as well  
314 as higher risk of MI and stroke individually in the UK Biobank. The association remained robust  
315 after adjustment for a wide variety of factors, did not differ appreciably by genetic risk for CVD,  
316 and was particularly strong in long sleepers and older individuals. These findings underscore  
317 the importance of maintaining consistent sleep duration for cardiovascular health and suggest

318 that promoting regular sleep duration may be a novel behavioral strategy for CVD risk reduction

319 that should be tested in intervention studies.

320

321

## 322 References

- 323 1. Kwok CS, Kontopantelis E, Kuligowski G, Gray M, Muhyaldeen A, Gale CP, Peat GM,  
324 Cleator J, Chew-Graham C, Loke YK, et al. Self-Reported Sleep Duration and Quality  
325 and Cardiovascular Disease and Mortality: A Dose-Response Meta-Analysis. *J Am Heart*  
326 *Assoc.* 2018;7:e008552. doi: 10.1161/jaha.118.008552
- 327 2. Zhao B, Meng Y, Jin X, Xi W, Ma Q, Yang J, Ma X, Yan B. Association of Objective and  
328 Self-Reported Sleep Duration With All-Cause and Cardiovascular Disease Mortality: A  
329 Community-Based Study. *J Am Heart Assoc.* 2023;12:e027832. doi:  
330 10.1161/jaha.122.027832
- 331 3. Wang S, Li Z, Wang X, Guo S, Sun Y, Li G, Zhao C, Yuan W, Li M, Li X, et al.  
332 Associations between sleep duration and cardiovascular diseases: A meta-review and  
333 meta-analysis of observational and Mendelian randomization studies. *Front Cardiovasc*  
334 *Med.* 2022;9:930000. doi: 10.3389/fcvm.2022.930000
- 335 4. Daghlas I, Dashti HS, Lane J, Aragam KG, Rutter MK, Saxena R, Vetter C. Sleep  
336 Duration and Myocardial Infarction. *J Am Coll Cardiol.* 2019;74:1304-1314. doi:  
337 10.1016/j.jacc.2019.07.022
- 338 5. Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, Grandner  
339 MA, Lavretsky H, Perak AM, Sharma G, et al. Life's Essential 8: Updating and  
340 Enhancing the American Heart Association's Construct of Cardiovascular Health: A  
341 Presidential Advisory From the American Heart Association. *Circulation.* 2022;146:e18-  
342 e43. doi: 10.1161/cir.0000000000001078
- 343 6. Buysse DJ. Sleep health: can we define it? Does it matter? *Sleep.* 2014;37:9-17. doi:  
344 10.5665/sleep.3298
- 345 7. Chung J, Goodman M, Huang T, Bertisch S, Redline S. Multidimensional sleep health in  
346 a diverse, aging adult cohort: Concepts, advances, and implications for research and  
347 intervention. *Sleep Health.* 2021;7:699-707. doi: 10.1016/j.sleh.2021.08.005
- 348 8. Huang T, Mariani S, Redline S. Sleep Irregularity and Risk of Cardiovascular Events:  
349 The Multi-Ethnic Study of Atherosclerosis. *J Am Coll Cardiol.* 2020;75:991-999. doi:  
350 10.1016/j.jacc.2019.12.054
- 351 9. Full KM, Huang T, Shah NA, Allison MA, Michos ED, Duprez DA, Redline S, Lutsey PL.  
352 Sleep Irregularity and Subclinical Markers of Cardiovascular Disease: The Multi-Ethnic  
353 Study of Atherosclerosis. *J Am Heart Assoc.* 2023;12:e027361. doi:  
354 10.1161/jaha.122.027361
- 355 10. Cribb L, Sha R, Yiallourou S, Grima NA, Cavuoto M, Baril AA, Pase MP. Sleep regularity  
356 and mortality: a prospective analysis in the UK Biobank. *Elife.* 2023;12. doi:  
357 10.7554/eLife.88359
- 358 11. Windred DP, Burns AC, Lane JM, Saxena R, Rutter MK, Cain SW, Phillips AJK. Sleep  
359 regularity is a stronger predictor of mortality risk than sleep duration: A prospective  
360 cohort study. *Sleep.* 2024;47. doi: 10.1093/sleep/zsad253
- 361 12. Chung J, Goodman MO, Huang T, Castro-Diehl C, Chen JT, Sofer T, Bertisch SM,  
362 Purcell SM, Redline S. Objectively regular sleep patterns and mortality in a prospective  
363 cohort: The Multi-Ethnic Study of Atherosclerosis. *J Sleep Res.* 2024;33:e14048. doi:  
364 10.1111/jsr.14048
- 365 13. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green  
366 J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a  
367 wide range of complex diseases of middle and old age. *PLoS Med.* 2015;12:e1001779.  
368 doi: 10.1371/journal.pmed.1001779
- 369 14. Doherty A, Jackson D, Hammerla N, Plötz T, Olivier P, Granat MH, White T, van Hees  
370 VT, Trenell MI, Owen CG, et al. Large Scale Population Assessment of Physical Activity

- 371 Using Wrist Worn Accelerometers: The UK Biobank Study. *PLoS One*.  
372 2017;12:e0169649. doi: 10.1371/journal.pone.0169649
- 373 15. van Hees VT, Fang Z, Zhao JH, Heywood J, Mirkes E, Sabia S. Package 'GGIR'. 2024.  
374 16. Jones SE, Lane JM, Wood AR, van Hees VT, Tyrrell J, Beaumont RN, Jeffries AR,  
375 Dashti HS, Hillsdon M, Ruth KS, et al. Genome-wide association analyses of chronotype  
376 in 697,828 individuals provides insights into circadian rhythms. *Nat Commun*.  
377 2019;10:343. doi: 10.1038/s41467-018-08259-7
- 378 17. van Hees VT, Sabia S, Jones SE, Wood AR, Anderson KN, Kivimäki M, Frayling TM,  
379 Pack AI, Bucan M, Trenell MI, et al. Estimating sleep parameters using an accelerometer  
380 without sleep diary. *Sci Rep*. 2018;8:12975. doi: 10.1038/s41598-018-31266-z
- 381 18. Fan M, Sun D, Zhou T, Heianza Y, Lv J, Li L, Qi L. Sleep patterns, genetic susceptibility,  
382 and incident cardiovascular disease: a prospective study of 385 292 UK biobank  
383 participants. *Eur Heart J*. 2020;41:1182-1189. doi: 10.1093/eurheartj/ehz849
- 384 19. Goodman MO, Cade BE, Shah NA, Huang T, Dashti HS, Saxena R, Rutter MK, Libby P,  
385 Sofer T, Redline S. Pathway-Specific Polygenic Risk Scores Identify Obstructive Sleep  
386 Apnea-Related Pathways Differentially Moderating Genetic Susceptibility to Coronary  
387 Artery Disease. *Circ Genom Precis Med*. 2022;15:e003535. doi:  
388 10.1161/circgen.121.003535
- 389 20. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment  
390 in epidemiologic studies. *Epidemiology*. 2009;20:488-495. doi:  
391 10.1097/EDE.0b013e3181a819a1
- 392 21. Einstein AJ, Shaw LJ, Hirschfeld C, Williams MC, Villines TC, Better N, Vitola JV, Cerci  
393 R, Dorbala S, Raggi P, et al. International Impact of COVID-19 on the Diagnosis of Heart  
394 Disease. *J Am Coll Cardiol*. 2021;77:173-185. doi: 10.1016/j.jacc.2020.10.054
- 395 22. Leger D, Richard JB, Collin O, Sauvet F, Faraut B. Napping and weekend catchup sleep  
396 do not fully compensate for high rates of sleep debt and short sleep at a population level  
397 (in a representative nationwide sample of 12,637 adults). *Sleep Med*. 2020;74:278-288.  
398 doi: 10.1016/j.sleep.2020.05.030
- 399 23. Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic  
400 stroke: incidence, prevalence, mortality, and risk factors. *Neurol Clin*. 2008;26:871-895,  
401 vii. doi: 10.1016/j.ncl.2008.07.003
- 402 24. Huang T, Redline S. Cross-sectional and Prospective Associations of Actigraphy-  
403 Assessed Sleep Regularity With Metabolic Abnormalities: The Multi-Ethnic Study of  
404 Atherosclerosis. *Diabetes Care*. 2019;42:1422-1429. doi: 10.2337/dc19-0596
- 405 25. Kianersi S, Wang H, Sofer T, Noordam R, Phillips A, Rutter MK, Redline S, Huang T.  
406 Association Between Accelerometer-Measured Irregular Sleep Duration and Type 2  
407 Diabetes Risk: A Prospective Cohort Study in the UK Biobank. *Diabetes Care*. 2024. doi:  
408 10.2337/dc24-0213
- 409 26. Smolensky MH, Hermida RC, Portaluppi F. Circadian mechanisms of 24-hour blood  
410 pressure regulation and patterning. *Sleep Med Rev*. 2017;33:4-16. doi:  
411 10.1016/j.smrv.2016.02.003
- 412 27. Poggiogalle E, Jamshed H, Peterson CM. Circadian regulation of glucose, lipid, and  
413 energy metabolism in humans. *Metabolism*. 2018;84:11-27. doi:  
414 10.1016/j.metabol.2017.11.017
- 415 28. Westgate EJ, Cheng Y, Reilly DF, Price TS, Walisser JA, Bradfield CA, FitzGerald GA.  
416 Genetic components of the circadian clock regulate thrombogenesis in vivo. *Circulation*.  
417 2008;117:2087-2095. doi: 10.1161/circulationaha.107.739227
- 418 29. Lo EH, Faraci FM. Circadian Mechanisms in Cardiovascular and Cerebrovascular  
419 Disease. *Circ Res*. 2024;134:615-617. doi: 10.1161/circresaha.124.324462
- 420 30. Man AWC, Li H, Xia N. Circadian Rhythm: Potential Therapeutic Target for  
421 Atherosclerosis and Thrombosis. *Int J Mol Sci*. 2021;22. doi: 10.3390/ijms22020676

- 422 31. McAlpine CS, Swirski FK. Circadian Influence on Metabolism and Inflammation in  
423 Atherosclerosis. *Circ Res*. 2016;119:131-141. doi: 10.1161/circresaha.116.308034
- 424 32. Tobaldini E, Costantino G, Solbiati M, Cogliati C, Kara T, Nobili L, Montano N. Sleep,  
425 sleep deprivation, autonomic nervous system and cardiovascular diseases. *Neurosci*  
426 *Biobehav Rev*. 2017;74:321-329. doi: 10.1016/j.neubiorev.2016.07.004
- 427 33. Leproult R, Van Cauter E. Role of sleep and sleep loss in hormonal release and  
428 metabolism. *Endocr Dev*. 2010;17:11-21. doi: 10.1159/000262524
- 429 34. Huang T, Poole EM, Vetter C, Rexrode KM, Kubzansky LD, Schernhammer E, Rohleder  
430 N, Hu FB, Redline S, Tworoger SS. Habitual sleep quality and diurnal rhythms of salivary  
431 cortisol and dehydroepiandrosterone in postmenopausal women.  
432 *Psychoneuroendocrinology*. 2017;84:172-180. doi: 10.1016/j.psyneuen.2017.07.484
- 433 35. Mars N, Lindbohm JV, Della Briotta Parolo P, Widén E, Kaprio J, Palotie A, Ripatti S.  
434 Systematic comparison of family history and polygenic risk across 24 common diseases.  
435 *Am J Hum Genet*. 2022;109:2152-2162. doi: 10.1016/j.ajhg.2022.10.009
- 436 36. Putilov AA. Sleep during "lockdown" highlighted the need to rethink the concept of  
437 weekend catch-up sleep. *Sleep Breath*. 2022;26:2001-2007. doi: 10.1007/s11325-021-  
438 02492-z
- 439 37. Yoshiike T, Kawamura A, Utsumi T, Matsui K, Kuriyama K. A prospective study of the  
440 association of weekend catch-up sleep and sleep duration with mortality in middle-aged  
441 adults. *Sleep Biol Rhythms*. 2023;21:409-418. doi: 10.1007/s41105-023-00460-6
- 442 38. Han KM, Lee HJ, Kim L, Yoon HK. Association between weekend catch-up sleep and  
443 high-sensitivity C-reactive protein levels in adults: a population-based study. *Sleep*.  
444 2020;43. doi: 10.1093/sleep/zsaa010
- 445 39. Sletten TL, Weaver MD, Foster RG, Gozal D, Klerman EB, Rajaratnam SMW,  
446 Roenneberg T, Takahashi JS, Turek FW, Vitiello MV, et al. The importance of sleep  
447 regularity: a consensus statement of the National Sleep Foundation sleep timing and  
448 variability panel. *Sleep Health*. 2023;9:801-820. doi: 10.1016/j.sleh.2023.07.016

449



Table 1. Characteristics of the study population by category of sleep duration irregularity

	7-day sleep duration standard deviation				
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min
N	12764	26018	22003	16503	8931
<b>Sociodemographic factors</b>					
Age at sleep study	63.7 (7.7)	63.0 (7.8)	62.3 (7.8)	61.5 (7.8)	60.5 (8.0)
Female, %	54	57	58	60	58
White, %	98	98	97	96	95
Townsend Deprivation Index	-2.0 (2.6)	-1.9 (2.7)	-1.7 (2.8)	-1.5 (2.9)	-1.3 (3.0)
<b>Work schedules</b>					
Employed no shiftwork, %	46	49	51	53	52
Employed with shiftwork, %	5	6	7	10	13
Retired/Do not work, %	49	45	42	38	35
<b>Genetic factors</b>					
Family history of CVD, %	61	61	60	60	57
PRS for CVD	-0.18 (0.96)	-0.16 (0.98)	-0.16 (0.97)	-0.15 (0.97)	-0.15 (0.97)
PRS for MI	-0.22 (0.95)	-0.21 (0.95)	-0.20 (0.95)	-0.19 (0.96)	-0.21 (0.95)
PRS for stroke	-0.11 (0.92)	-0.08 (0.93)	-0.08 (0.93)	-0.06 (0.93)	-0.06 (0.93)
<b>Lifestyle factors</b>					
Body mass index, kg/m <sup>2</sup>	26.2 (4.2)	26.4 (4.4)	26.7 (4.5)	27.1 (4.7)	27.3 (5.0)
Current Smoker, %	5	6	6	8	9
Current alcohol drinker, %	95	95	95	94	93
Healthy diet score	3.2 (1.2)	3.2 (1.2)	3.1 (1.2)	3.1 (1.2)	3.1 (1.3)
Physical activity, MET-hrs/week	34.6 (38.9)	35.0 (39.9)	34.7 (40.5)	34.6 (40.6)	34.7 (40.8)
<b>Clinical factors</b>					
Dislipidemia, %	18	18	17	18	17
Hypertension, %	25	26	26	27	25
Diabetes, %	3	4	4	4	4
Depression status, <sup>1</sup> %	31	32	35	37	37
<b>Sleep-related factors</b>					
Average sleep duration	7.5 (0.8)	7.4 (0.8)	7.4 (0.8)	7.3 (0.8)	6.6 (1.0)
<b>Sleep duration categories</b>					
<7 hrs, %	26	28	31	37	67
7-8 hrs, %	51	50	48	45	26
>8 hrs, %	23	22	20	18	8
Sleep efficiency	0.77 (0.07)	0.77 (0.07)	0.76 (0.07)	0.75 (0.07)	0.73 (0.09)
<b>Chronotype</b>					
Morning type, %	23	24	24	23	22
Intermediate type, %	70	69	68	67	67
Evening type, %	6	7	8	10	11
<b>Insomnia symptoms</b>					
Never/rarely, %	25	25	25	25	26
Sometimes, %	49	48	48	47	47
Usually, %	26	27	27	28	27
<b>Daytime sleepiness</b>					

Never/rarely, %	79	79	78	77	78
Sometimes, %	19	19	19	20	19
Usually, %	2	2	2	2	3
Sleep apnea, %	1	1	1	1	1

---

Values are means (SD) for continuous variables and percentages for categorical variables.

<sup>1</sup>Based on self-reported depressive symptoms or self-reported clinic visits for depression

Table 2. Associations of accelerometer-measured sleep duration irregularity with incident cardiovascular events in the UK Biobank

	7-day sleep duration standard deviation					Per 1 hour	P-trend
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min		
<b>Major cardiovascular events</b>							
Cases	327	691	589	455	248	2310	
Person-years	94088	192004	162509	121711	65945	636258	
Model 1	Ref	1.10 (0.97, 1.26)	1.19 (1.04, 1.37)	1.33 (1.15, 1.53)	1.40 (1.18, 1.65)	1.19 (1.10, 1.27)	<.0001
Model 2	Ref	1.09 (0.95, 1.24)	1.15 (1.01, 1.32)	1.25 (1.08, 1.44)	1.31 (1.11, 1.55)	1.15 (1.07, 1.24)	0.0001
Model 3	Ref	1.09 (0.95, 1.24)	1.15 (1.00, 1.31)	1.24 (1.07, 1.43)	1.27 (1.07, 1.50)	1.13 (1.05, 1.22)	0.001
<b>Myocardial infarction</b>							
Cases	176	331	310	228	138	1183	
Person-years	94454	192993	163280	122333	66255	639316	
Model 1	Ref	0.98 (0.82, 1.18)	1.16 (0.96, 1.40)	1.21 (0.99, 1.48)	1.39 (1.11, 1.74)	1.23 (1.11, 1.35)	<.0001
Model 2	Ref	0.96 (0.80, 1.15)	1.11 (0.92, 1.33)	1.12 (0.92, 1.36)	1.28 (1.02, 1.60)	1.18 (1.07, 1.31)	0.001
Model 3	Ref	0.96 (0.80, 1.15)	1.09 (0.91, 1.31)	1.10 (0.90, 1.34)	1.20 (0.96, 1.51)	1.15 (1.04, 1.27)	0.008
<b>Stroke</b>							
Cases	159	369	290	237	120	1175	
Person-years	94519	192940	163443	122385	66379	639665	
Model 1	Ref	1.21 (1.01, 1.46)	1.21 (1.00, 1.47)	1.44 (1.18, 1.77)	1.43 (1.13, 1.82)	1.17 (1.05, 1.29)	0.003
Model 2	Ref	1.20 (1.00, 1.45)	1.19 (0.98, 1.44)	1.38 (1.13, 1.70)	1.38 (1.08, 1.75)	1.15 (1.03, 1.27)	0.01
Model 3	Ref	1.20 (1.00, 1.45)	1.19 (0.98, 1.44)	1.38 (1.13, 1.70)	1.36 (1.07, 1.74)	1.14 (1.03, 1.27)	0.01

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD

Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

Model 3: Model 2 + adjusted for accelerometer-measured average sleep duration and sleep efficiency, self-reported insomnia symptoms, chronotype and daytime sleepiness, and clinically diagnosed sleep apnea based on ICD-10

Table 3. Subgroup analysis of the association between accelerometer-measured sleep duration irregularity and cardiovascular disease risk in the UK Biobank


	Cases/N	HR (95% CI) <sup>1</sup>	P-int
Age			0.04
<60 yrs	393/31903	1.02 (0.86, 1.20)	
≥60 yrs	1917/54316	1.23 (1.13, 1.33)	
Sex			0.09
Men	1414/36651	1.22 (1.11, 1.33)	
Women	896/49568	1.13 (1.00, 1.27)	
Race			0.42
White	2242/83577	1.19 (1.11, 1.28)	
Non-white	68/2642	1.01 (0.68, 1.51)	
Average sleep duration			0.006
<7 hrs	876/29488	1.07 (0.97, 1.18)	
7-8 hrs	983/39890	1.22 (1.07, 1.40)	
>8 hrs	451/16841	1.52 (1.23, 1.89)	
Family history of CVD			0.03
No	759/34288	1.07 (0.94, 1.22)	
Yes	1551/51931	1.24 (1.14, 1.35)	
PRS <sup>2</sup>			0.43
Low	544/28033	1.17 (1.01, 1.36)	
Medium	721/28034	1.34 (1.19, 1.51)	
High	991/28034	1.09 (0.97, 1.22)	

<sup>1</sup>Adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD


<sup>2</sup>Among 84101 participants with genotyping information with additional adjustment of the first three genetic principal components

Figure 1. Risk of incident cardiovascular events according to joint categories of sleep duration irregularity and (a) polygenic risk score for CVD and (b) average sleep duration. Estimates adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD (plus the first three genetic principal components for joint associations with the polygenic risk score).

(a)



(b)



Supplemental Table 1. Associations of accelerometer-measured sleep duration irregularity with incident cardiovascular events in the UK Biobank, censored at the start of the COVID-19 pandemic lockdown (March 23, 2020)

	7-day sleep duration standard deviation					Per 1 hour	P-trend
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min		
<b>Major cardiovascular events</b>							
Cases	205	449	393	304	173	1524	
Person-years	69140	140444	119186	89709	50157	468635	
Model 1	Ref	1.15 (0.98, 1.36)	1.28 (1.08, 1.51)	1.42 (1.19, 1.69)	1.51 (1.23, 1.85)	1.24 (1.13, 1.35)	<.0001
Model 2	Ref	1.13 (0.96, 1.34)	1.23 (1.04, 1.46)	1.32 (1.11, 1.58)	1.41 (1.15, 1.72)	1.20 (1.10, 1.31)	<.0001
Model 3	Ref	1.13 (0.96, 1.33)	1.22 (1.03, 1.45)	1.31 (1.09, 1.57)	1.35 (1.10, 1.67)	1.17 (1.07, 1.28)	0.0008
<b>Myocardial infarction</b>							
Cases	109	218	213	160	97	797	
Person-years	69323	140940	119576	90017	50329	470185	
Model 1	Ref	1.05 (0.83, 1.32)	1.29 (1.03, 1.63)	1.38 (1.08, 1.76)	1.54 (1.17, 2.03)	1.30 (1.15, 1.46)	<.0001
Model 2	Ref	1.03 (0.82, 1.30)	1.23 (0.98, 1.55)	1.26 (0.99, 1.62)	1.41 (1.07, 1.86)	1.25 (1.11, 1.41)	0.0003
Model 3	Ref	1.02 (0.81, 1.29)	1.21 (0.96, 1.52)	1.23 (0.96, 1.57)	1.30 (0.98, 1.73)	1.20 (1.06, 1.35)	0.004
<b>Stroke</b>							
Cases	101	235	187	152	81	756	
Person-years	69353	140907	119671	90035	50394	470359	
Model 1	Ref	1.22 (0.97, 1.55)	1.24 (0.98, 1.58)	1.46 (1.14, 1.88)	1.47 (1.10, 1.98)	1.19 (1.04, 1.35)	0.009
Model 2	Ref	1.21 (0.96, 1.52)	1.21 (0.95, 1.54)	1.39 (1.08, 1.79)	1.40 (1.05, 1.89)	1.16 (1.02, 1.33)	0.02
Model 3	Ref	1.21 (0.96, 1.53)	1.21 (0.95, 1.55)	1.40 (1.09, 1.81)	1.41 (1.04, 1.90)	1.16 (1.01, 1.33)	0.03

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD

Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

Model 3: Model 2 + adjusted for accelerometer-measured average sleep duration and sleep efficiency, self-reported insomnia symptoms, chronotype and daytime sleepiness, and clinically diagnosed sleep apnea based on ICD-10

Supplemental Table 2. Associations of accelerometer-measured sleep duration irregularity with incident cardiovascular events in the UK Biobank, excluding cases diagnosed in the first year of follow-up

	7-day sleep duration standard deviation					Per 1 hour	P-trend
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min		
<b>Major cardiovascular events</b>							
Cases	303	613	520	401	203	2040	
Person-years	94060	191940	162456	121669	65916	636041	
Model 1	Ref	1.06 (0.92, 1.21)	1.14 (0.99, 1.31)	1.27 (1.09, 1.47)	1.24 (1.04, 1.48)	1.14 (1.06, 1.23)	0.001
Model 2	Ref	1.04 (0.91, 1.20)	1.10 (0.96, 1.27)	1.20 (1.03, 1.39)	1.17 (0.98, 1.40)	1.11 (1.03, 1.20)	0.01
Model 3	Ref	1.04 (0.91, 1.19)	1.10 (0.95, 1.26)	1.18 (1.02, 1.38)	1.13 (0.94, 1.36)	1.09 (1.01, 1.19)	0.03
<b>Myocardial infarction</b>							
Cases	164	299	271	199	111	1044	
Person-years	94431	192949	163240	122300	66232	639152	
Model 1	Ref	0.95 (0.79, 1.15)	1.09 (0.90, 1.32)	1.14 (0.92, 1.40)	1.21 (0.95, 1.54)	1.17 (1.05, 1.30)	0.004
Model 2	Ref	0.93 (0.77, 1.13)	1.04 (0.85, 1.26)	1.05 (0.85, 1.29)	1.11 (0.87, 1.41)	1.13 (1.01, 1.26)	0.03
Model 3	Ref	0.93 (0.77, 1.12)	1.02 (0.84, 1.24)	1.03 (0.84, 1.27)	1.05 (0.82, 1.34)	1.10 (0.98, 1.23)	0.1
<b>Stroke</b>							
Cases	147	322	260	211	101	1041	
Person-years	94495	192891	163410	122354	66359	639509	
Model 1	Ref	1.14 (0.94, 1.39)	1.18 (0.96, 1.44)	1.39 (1.13, 1.72)	1.31 (1.02, 1.69)	1.14 (1.02, 1.27)	0.02
Model 2	Ref	1.13 (0.93, 1.38)	1.16 (0.95, 1.42)	1.34 (1.09, 1.66)	1.26 (0.98, 1.63)	1.12 (1.00, 1.25)	0.04
Model 3	Ref	1.14 (0.93, 1.38)	1.16 (0.95, 1.42)	1.34 (1.08, 1.66)	1.25 (0.97, 1.63)	1.11 (0.99, 1.25)	0.06

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD

Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

Model 3: Model 2 + adjusted for accelerometer-measured average sleep duration and sleep efficiency, self-reported insomnia symptoms, chronotype and daytime sleepiness, and clinically diagnosed sleep apnea based on ICD-10



Supplemental Table 3. Associations of accelerometer-measured sleep duration irregularity on weekdays with incident cardiovascular events in the UK Biobank

	7-day sleep duration standard deviation					Per 1 hour	P-trend
	≤30 min	31-45 min	46-60 min	60-90 min	>90 min		
<b>Major cardiovascular events</b>							
Cases	277	408	380	508	411	1984	
Person-years	84861	122075	111436	138939	96557	553867	
Model 1	Ref	1.00 (0.86, 1.17)	1.03 (0.88, 1.20)	1.09 (0.94, 1.26)	1.24 (1.07, 1.45)	1.18 (1.09, 1.28)	<.0001
Model 2	Ref	1.00 (0.85, 1.16)	1.01 (0.86, 1.17)	1.04 (0.90, 1.20)	1.15 (0.99, 1.35)	1.13 (1.04, 1.22)	0.003
Model 3	Ref	1.00 (0.85, 1.16)	1.00 (0.86, 1.17)	1.03 (0.89, 1.20)	1.14 (0.97, 1.33)	1.12 (1.03, 1.21)	0.005
<b>Myocardial infarction</b>							
Cases	141	203	178	263	205	990	
Person-years	85221	122592	111986	139666	97108	556573	
Model 1	Ref	0.99 (0.80, 1.23)	0.96 (0.77, 1.20)	1.13 (0.92, 1.39)	1.26 (1.02, 1.57)	1.19 (1.06, 1.32)	0.002
Model 2	Ref	0.98 (0.79, 1.21)	0.93 (0.74, 1.16)	1.06 (0.86, 1.30)	1.14 (0.92, 1.42)	1.11 (1.00, 1.24)	0.05
Model 3	Ref	0.98 (0.79, 1.22)	0.92 (0.74, 1.15)	1.05 (0.85, 1.29)	1.12 (0.90, 1.39)	1.10 (0.98, 1.23)	0.09
<b>Stroke</b>							
Cases	139	214	212	253	214	1032	
Person-years	85272	122666	111941	139716	97129	556725	
Model 1	Ref	1.04 (0.84, 1.29)	1.13 (0.91, 1.40)	1.06 (0.86, 1.30)	1.24 (1.00, 1.54)	1.18 (1.06, 1.31)	0.002
Model 2	Ref	1.03 (0.83, 1.28)	1.11 (0.90, 1.38)	1.02 (0.83, 1.26)	1.18 (0.95, 1.46)	1.14 (1.02, 1.27)	0.02
Model 3	Ref	1.03 (0.83, 1.28)	1.11 (0.90, 1.38)	1.02 (0.83, 1.26)	1.17 (0.94, 1.45)	1.14 (1.02, 1.27)	0.02

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD

Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

Model 3: Model 2 + adjusted for accelerometer-measured average sleep duration and sleep efficiency, self-reported insomnia symptoms, chronotype and daytime sleepiness, and clinically diagnosed sleep apnea based on ICD-10

Supplemental Table 4. Associations of accelerometer-measured sleep duration irregularity with risk of ischemic and hemorrhagic stroke in the UK Biobank

	7-day sleep duration standard deviation					Per 1 hour	P-trend
	<30 min	30-44 min	45-59 min	60-89 min	≥90 min		
<b>Ischemic stroke</b>							
Cases	118	266	211	186	98	879	
Person-years	94519	192940	163443	122385	66379	639665	
Model 1	Ref	1.18 (0.95, 1.47)	1.20 (0.96, 1.50)	1.54 (1.22, 1.94)	1.59 (1.21, 2.08)	1.24 (1.10, 1.39)	0.0003
Model 2	Ref	1.17 (0.94, 1.46)	1.17 (0.93, 1.47)	1.47 (1.17, 1.86)	1.51 (1.16, 1.99)	1.21 (1.08, 1.36)	0.001
Model 3	Ref	1.18 (0.95, 1.46)	1.18 (0.94, 1.48)	1.48 (1.17, 1.87)	1.52 (1.15, 2.00)	1.21 (1.08, 1.37)	0.002
<b>Hemorrhagic stroke</b>							
Cases	44	105	81	55	24	309	
Person-years	94519	192940	163443	122385	66379	639665	
Model 1	Ref	1.23 (0.87, 1.75)	1.20 (0.83, 1.74)	1.18 (0.79, 1.76)	1.02 (0.62, 1.68)	0.97 (0.78, 1.21)	0.79
Model 2	Ref	1.22 (0.86, 1.74)	1.19 (0.82, 1.72)	1.15 (0.77, 1.72)	1.00 (0.61, 1.65)	0.96 (0.77, 1.20)	0.72
Model 3	Ref	1.21 (0.85, 1.73)	1.17 (0.81, 1.70)	1.13 (0.75, 1.68)	0.96 (0.58, 1.60)	0.94 (0.75, 1.18)	0.61

Model 1: adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD

Model 2: Model 1 + adjusted for BMI, smoking status, alcohol consumption, diet quality, physical activity, and history of hypertension, dyslipidemia, diabetes and depression

Model 3: Model 2 + adjusted for accelerometer-measured average sleep duration and sleep efficiency, self-reported insomnia symptoms, chronotype and daytime sleepiness, and clinically diagnosed sleep apnea based on ICD-10

Supplementary Table 5. Subgroup analysis of the association between accelerometer-measured sleep duration irregularity and risk of myocardial infarction and stroke in the UK Biobank


	Myocardial infarction			Stroke		
	Cases/N	HR (95% CI) <sup>1</sup>	P-int	Cases/N	HR (95% CI) <sup>1</sup>	P-int
Age			0.04			0.27
<60 yrs	228/31903	1.02 (0.82, 1.27)		171/31903	1.02 (0.79, 1.32)	
≥60 yrs	955/54316	1.29 (1.16, 1.44)		1004/54316	1.20 (1.07, 1.34)	
Sex			0.87			0.04
Men	792/36651	1.21 (1.07, 1.36)		653/36651	1.27 (1.11, 1.44)	
Women	391/49568	1.26 (1.06, 1.49)		522/49568	1.04 (0.88, 1.23)	
Race			0.81			0.20
White	1144/83577	1.23 (1.12, 1.36)		1145/83577	1.18 (1.07, 1.31)	
Non-white	39/2642	1.14 (0.70, 1.86)		30/2642	0.76 (0.38, 1.54)	
Average sleep duration			0.46			0.0003
<7 hrs	483/29488	1.12 (0.99, 1.27)		416/29488	1.01 (0.87, 1.17)	
7-8 hrs	486/39890	1.24 (1.03, 1.50)		513/39890	1.26 (1.05, 1.51)	
>8 hrs	214/16841	1.34 (0.95, 1.87)		246/16841	1.73 (1.32, 2.27)	
Family history of CVD			0.005			0.75
No	363/34288	1.00 (0.82, 1.22)		405/34288	1.15 (0.97, 1.34)	
Yes	820/51931	1.33 (1.19, 1.49)		770/51931	1.18 (1.04, 1.34)	
PRS <sup>2</sup>			0.22			0.79
Low	198/28033	1.41 (1.14, 1.76)		318/28033	1.00 (0.80, 1.25)	
Medium	358/28034	1.29 (1.08, 1.54)		373/28035	1.34 (1.13, 1.58)	
High	599/28034	1.13 (0.98, 1.31)		456/28033	1.14 (0.96, 1.35)	

<sup>1</sup>Adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD


<sup>2</sup>Among 84101 participants with genotyping information with additional adjustment of the first three genetic principal components

Supplemental Figure 1. Risk of incident MI (a) or stroke (b) according to joint categories of sleep duration irregularity and polygenic risk score for MI or stroke. Estimates adjusted for age, sex, race, Townsend deprivation index, work schedules, family history of CVD, and the first three genetic principal components.

(a) MI




(b) Stroke



Supplemental Figure 2. Risk of incident MI (a) or stroke (b) according to joint categories of sleep duration irregularity and average sleep duration. Estimates adjusted for age, sex, race, Townsend deprivation index, work schedules, and family history of CVD.

(a) MI



(b) Stroke

